- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06718764
Sistema de monitoramento de cabeceira Neurosteer
Avaliando a viabilidade da utilização de um novo monitor de atividade cerebral na unidade de terapia intensiva de neurociências
The purpose of this study is to evaluate the clinical utility of Neurosteer's brain monitoring platform for monitoring delirium, sedation, and agitation in intubated and sedated ICU patients. The research team will be conducting a single-site study. The research team will enroll 100 patients admitted to the NSICU. 50 of these patients will have Acute Neurological Injuries (ANI) and the other 50 will not have an ANI. All enrolled patients will receive the intervention, the Neurosteer brain monitoring device.
The study intervention consists of the use of Neurosteer's innovative single-channel EEG monitoring device to determine if there is a good correlation and agreement between their signals/parameters to RASS, CAM-ICU, and continuous EEG monitoring readings. The Neurosteer device will be attached to their forehead and readings will be collected for the duration of their NSICU stay. The research team will adapt the current physical methods of detecting the depth of anesthesia i.e. through the Richmond Agitation-Sedation Scale (RASS) & CAM-ICU, to auditory stimulation, which will be delivered through earphones with no physical contact, with the aim of achieving a high correlation between the methods. RASS and CAM-ICU will be collected hourly as standard of care and Neurosteer auditory stimulation will be done 3-4 times a day to coincide with RASS and 1-2 times a day to coincide with CAM-ICU. The research team will correlate collected hourly RASS and CAM-ICU assessments with Neurosteer derived signals and parameters.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
In the study population of sedated, intubated critically ill patients, the research team hypothesize the following:
- Neurosteer's derived signals and parameters will be correlated to and will have at least fair agreement with the Richmond Agitation Sedation Scale (RASS) for measuring depth of sedation.
- Neurosteer's derived signals and parameters will be correlated to and have at least fair agreement with the Confusion Assessment Method (CAM-ICU) to screen for and diagnose delirium.
- For enrolled patients undergoing cEEG monitoring as standard of care, the detection of burst suppression, seizures, and ictal-interictal continuum between Neurosteer's derived signals and parameters and continuous EEG monitoring readings will be correlated and have at least fair agreement.
- There will be no significant difference in the correlations determined in our primary objective between NSICU patients with and without ANI.
The research team will be conducting a single-site study to evaluate these hypotheses. The research team will enroll 100 patients admitted to the NSICU. 50 of these patients will have an ANI and the other 50 will not have an ANI. The research team will define ANI as subjects having Acute Ischemic Stroke (AIS), Intracerebral Hemorrhage, Subarachnoid Hemorrhage (SAH), Status Epileptics, Traumatic Brain Injury (TBI), Brain Tumors, Meningitis/encephalitis, post cardiac arrest hypoxic ischemic encephalopathy. The research team will define subject without ANI to have neuromuscular disorders such as myasthenia gravis, spine surgery, septic shock, acute respiratory distress syndrome, and Hemorrhagic shock ex. from gastrointestinal bleeding. The research team will obtain written informed consent from all patients and/or their Legally Authorized Representative (LAR) to conduct the study. All enrolled patients will receive the intervention, the Neurosteer brain monitoring platform. Intra-individual comparisons will be made between standard of care assessments and the findings of the Neurosteer device. Inter-individual comparisons between patients with and without ANI will also be made. Statistical analyses will be conducted halfway through study enrollment and upon completion of enrollment and data entry. The study intervention will span the duration of the patient's admission in the NSICU. Patients will be screened for consented and screened for eligibility as they get admitted to the NSICU.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Leslie Melo, MPH
- Número de telefone: 212-241-3376
- E-mail: leslie.melo@mountsinai.org
Locais de estudo
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Recrutamento
- Mount Sinai Hospital
-
Investigador principal:
- Neha S Dangayach
-
Contato:
- Neha S Dangayach, MD, MSCR, FNCS, FAAN, DCE'21
- Número de telefone: 212-241-3374
- E-mail: neha.dangayach@mountsinai.org
-
Contato:
- Leslie Melo, MPH
- E-mail: leslie.melo@mountsinai.org
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Provision of signed and dated informed consent form from patient and/or LAR, including stated willingness to comply with all study procedures and availability for the duration of the study
- Any assigned sex at birth, including individuals who are transgender or intersex
- Age 18 years or older
- Mechanically ventilated patients with an anticipated LOS >/=48 hours on any sedative drips including propofol, midazolam, dexmedetomidine, fentanyl, dialudid, ketamine
Exclusion Criteria:
- Has known hearing problems and usage of hearing aids
- Has a rash on forehead
- History of polysubstance abuse
- Severe dementia
- Anticipated Withdrawing Life-Sustaining Therapy (WLST) within the next 24-48 hours
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: NSICU Patients with Acute Neurological Injuries (ANI)
ANI are participants having Acute Ischemic Stroke (AIS), Intracerebral Hemorrhage, Subarachnoid Hemorrhage (SAH), Status Epileptics, Traumatic Brain Injury (TBI), Brain Tumors, Meningitis/encephalitis, post cardiac arrest hypoxic ischemic encephalopathy. All participants will be set up with the Neurosteer bedside monitoring system. |
Neurosteer device will be attached to participants forehead and readings will be collected for the duration of their NSICU stay. Neurosteer auditory stimulation will be done 3-4 times a day to coincide with RASS and 1-2 times a day to coincide with CAM-ICU. The research team will correlate collected hourly RASS and CAM-ICU assessments with Neurosteer derived signals and parameters. |
|
Comparador Ativo: NSICU Patients without Acute Neurological Injuries (ANI)
Participants without ANI to have neuromuscular disorders such as myasthenia gravis, spine surgery, septic shock, acute respiratory distress syndrome, and Hemorrhagic shock ex. from gastrointestinal bleeding. All participants will be set up with the Neurosteer bedside monitoring system. |
Neurosteer device will be attached to participants forehead and readings will be collected for the duration of their NSICU stay. Neurosteer auditory stimulation will be done 3-4 times a day to coincide with RASS and 1-2 times a day to coincide with CAM-ICU. The research team will correlate collected hourly RASS and CAM-ICU assessments with Neurosteer derived signals and parameters. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sedation as measured by Richmond Agitation Sedation Scale
Prazo: 3-4 times daily throughout participants NSICU stay (average 14 days)
|
Richmond Agitation Sedation Scale (RASS) for measuring the depth of sedation in sedated, intubated critically ill patients. RASS scoring -5 to +4, is a valid and reliable instrument to assess level of sedation and agitated behavior during sedation, where higher scores indicate higher levels of agitation. 4 Combative, violent, danger to staff 3 Pulls or removes tube(s) or catheters; aggressive 2 Frequent non-purposeful movement 1 Anxious, apprehensive, but not aggressive 0 Alert and calm
|
3-4 times daily throughout participants NSICU stay (average 14 days)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Delirium as measured by Confusion Assessment Method (CAM)
Prazo: 1-2 times daily throughout participants NSICU stay (average 14 days)
|
Confusion Assessment Method (CAM) for screening and diagnosing delirium in intubated, sedated critically ill patients. The CAM consists of 4 features: 1-Onset, 2-Inattention, 3-Disorganized thinking, and 4-altered level of consciousness. The diagnosis of delirium by CAM is based on the presence of features 1 and 2, and either 3 or 4. |
1-2 times daily throughout participants NSICU stay (average 14 days)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Neha S Dangayach, MD, MSCR, FNCS, FAAN, DCE'21, Icahn School of Medicine at Mount Sinai
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Comportamento motor aberrante na demência
- Manifestações Neurológicas
- Doenças do Sistema Nervoso
- Transtornos Mentais, Desordem Mental
- Sintomas Comportamentais
- Confusão
- Manifestações Neurocomportamentais
- Distúrbios Neurocognitivos
- Discinesias
- Distúrbios psicomotores
- Condições Patológicas, Sinais e Sintomas
- Comportamento
- Sinais e sintomas
- Delírio
- Agitação Psicomotora
Outros números de identificação do estudo
- STUDY-23-00018
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The research team will only share aggregated, de-identified data with the sponsor solely for the purpose of analyzing correlations.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .